

## Valneva Announces the Availability of Documentation for its Meeting of Shareholders

**Saint-Herblain (France), June 6, 2019** – The Shareholders of Valneva SE (“Valneva” or “the Company”) are invited to participate in the Company’s Combined Shareholders’ Meeting to be held on June 27, 2019 at 2:00 p.m. CET, at the Hotel InterContinental Paris - Le Grand, 2 rue Scribe, 75009 Paris - France.

The preliminary notices of the meeting, including the agenda, the proposed resolutions and instructions for participation and voting, were published in the *Bulletin des Annonces Légales Obligatoires* (BALO) on May 22, 2019. Documents and information relating to the meetings are available on Valneva’s website at [www.valneva.com/en/investorsmedia/agm](http://www.valneva.com/en/investorsmedia/agm).

In accordance with applicable law, registered shareholders can, by letter or email, request that the Company provide the meeting documents listed in the French commercial code until the fifth working day before the meeting (please refer to the contact details below).

Holders of bearer shares may exercise this right on the condition that they provide a certificate of share ownership issued by an authorized financial institution.

Shareholders may also access the documents at the Company’s registered office.

### About Valneva SE

Valneva is a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs. Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO®/JESPECT® indicated for the prevention of Japanese encephalitis and DUKORAL® indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has various vaccines in development including a unique vaccine against Lyme disease. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the U.S. with approximately 480 employees. More information is available at [www.valneva.com](http://www.valneva.com).

### Valneva Legal Department Contact

Valneva SE  
Legal Department  
6 rue Alain Bombard,  
44800 Saint-Herblain, France  
Email: [assemblee.generale@valneva.com](mailto:assemblee.generale@valneva.com)

### Valneva Investor and Media Contacts

Laetitia Bachelot-Fontaine  
Global Head of Investor Relations &  
Corporate Communications  
M +33 (0)6 4516 7099  
[investors@valneva.com](mailto:investors@valneva.com)

Teresa Pinzolit  
Corporate Communications Specialist  
T +43 (0)1 20620 1116  
[communications@valneva.com](mailto:communications@valneva.com)

### **Forward-Looking Statements**

This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to the progress, timing and completion of research, development and clinical trials for product candidates, the ability to manufacture, market, commercialize and achieve market acceptance for product candidates, the ability to protect intellectual property and operate the business without infringing on the intellectual property rights of others, estimates for future performance and estimates regarding anticipated operating losses, future revenues, capital requirements and needs for additional financing. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be indicative of their in the future. In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made during this presentation will in fact be realized. Valneva is providing the information in these materials as of this press release, and disclaim any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

